Treatment

NNC0662-0419 clinical trials

Active studies that list NNC0662-0419 as an intervention or treatment.

4active studies

3recruiting now

11countries represented

63largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

Diabetes Mellitus, Type 2Condition

NNC0662-0419, SemaglutideTreatment

Croatia, Hungary63 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07415954See eligibility →

Recruiting nowPhase 2

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Recruiting nowPhase 1

Overweight, ObesityCondition

NNC0662-0419, Oral contraceptiveTreatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-04-24 · NCT07525791See eligibility →

Active, not recruitingPhase 2

Overweight, ObesityCondition

NNC0662-0419, PlaceboTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-05-07 · NCT07184632See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.